incretin glp 1 hormones and the satiation signal Dr.Syed - GLP-1 & GIP

In a mouse model of osteoarthritis induced by destabilization of the medial meniscus, glycoursodeoxycholic acid was found to mitigate disease progression, an effect associated with an increase in intestinal L cell numbers (87)

Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms

Before switching, a clinician would need to review: Which treatment you are currently taking Your current dose How long you have been taking it Your side effects Your weight loss progress Your medical history Your other medication Switching is not just a straight swap

It would be important to reassess this pattern now with more widespread adoption of GLP-1s for obesity alone, since the study period ended in 2022

What Are the Negative Side Effects of GLP-1 Drugs

This is where the strategy needs to change